Why will the biological flow of Hualan decrease in 2020?

The financial report data shows that the decline in performance is related to the impact of the epidemic and the full transformation of Hualan. For a long time, blood products bosses have been eating and drinking under high barriers in the industry, but in the face of market competition, revenue growth is becoming more and more difficult.

In the first half of 2020, there were no targeted drugs in COVID-19 at that time, but refined ice was urgently used to treat COVID-19 patients because it could improve their immunity. Therefore, in the first half of last year, the revenue of Hualan Bio-static C was 525 million yuan, which was the best performance in the past four years. But with the epidemic under control, Jingping's sales gradually returned to normal. Not only Hualan Bio, but also the static C revenue of Shanghai Lai Shi in the first half of this year decreased by 9.74%.